The study included 639 patients, 79.8% of whom had previously received covalent BTK inhibitors.
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca ...
In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to ...
New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional ...
Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...
Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results